PIK3CB and breast cancer: The PI3K catalytic subunit inhibitor BKM120, the mTOR inhibitor RAD001, and the dual PI3K/mTOR inhibitor BGT226 were tested against ER+ breast cancer cell lines before and following long-term estrogen deprivation (LTED).